Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial
Official title:
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in Autosomal Dominant Polycystic Kidney Disease (ADPKD): The GeneQuest Study
The aim of this study is to identify families with ADPKD , characterize the phenotype and screen for mutations in known genes (PKD1 and PKD2, and then HNF1b and UMOD in PKD1 PKD2 negative carriers). Genome wide analysis will be performed in families without mutations identified.
- Inclusion of ADPKD patients in 20 different centers of Nephrology in the Western part of France - Characterization of the Phenotype - Collect DNA sample - Analysis of PKD1 and PKD2 genes first - Analysis of HNFIb and UMOD for PKD1 and PKD2 negative patients - Recruitment of affected and non-affected relatives of PKD1 and PKD2 negative ADPKD patients - Identify new genes involved in ADPKD using exome sequencing in PKD1 and PKD2 negative pedigrees ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02964273 -
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
|
Phase 3 | |
| Terminated |
NCT01223755 -
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
|
Phase 2/Phase 3 | |
| Completed |
NCT01280721 -
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
|
Phase 3 | |
| Completed |
NCT01214421 -
Tolvaptan Extension Study in Participants With ADPKD
|
Phase 3 | |
| Completed |
NCT02225860 -
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT01616927 -
Study of Lanreotide to Treat Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01430494 -
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Completed |
NCT00346918 -
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT03949894 -
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT02925221 -
Canadian Medical Assessment of JINARC™ Outcomes Registry
|
||
| Completed |
NCT04689074 -
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
|
||
| Terminated |
NCT02616055 -
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
|
Phase 2 | |
| Recruiting |
NCT06289998 -
Study of Tamibarotene in Patients With ADPKD
|
Phase 2 | |
| Recruiting |
NCT02115659 -
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT00309283 -
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
|
Phase 3 | |
| Recruiting |
NCT06345755 -
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
|
Phase 1 |